Satavaptan is a vasopressin V2 receptor antagonist that has been shown to improve hyponatremia in patients with cirrhosis, congestive heart failure, and syndrome of inappropriate antidiuresis. It is grouped under the following drug class(es): Diuretics. Its therapeutic use is listed as hyponatremia agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Satavaptan [INN] and Aquilda. Its PubChem CID is 158348.
Satavaptan
| CAS No | 185913-78-4 |
|---|---|
| Molecular Formula | C33H45N3O8S |
| Molecular Weight | 643.8 g/mol |
| Synonyms | N-tert-butyl-4-[5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indole]-1'-yl]sulfonyl-3-methoxybenzamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Satavaptan is a vasopressin V2 receptor antagonist that has been shown to improve hyponatremia in patients with cirrhosis, congestive heart failure, and syndrome of inappropriate antidiuresis.
The listed CAS number is 185913-78-4.
The listed molecular formula is C33H45N3O8S.
The listed molecular weight is 643.8 g/mol.
N-tert-butyl-4-[5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indole]-1'-yl]sulfonyl-3-methoxybenzamide.
The source lists Satavaptan [INN] and Aquilda.